Breaking News Instant updates and real-time market news.

REGN

Regeneron

$319.61

-8.98 (-2.73%)

08:51
04/09/18
04/09
08:51
04/09/18
08:51

Regeneron downgraded to Market Perform on valuation at Raymond James

As previously reported, Raymond James downgraded Regeneron to Market Perform from Outperform. Analyst Laura Chico said Regeneron has one of biotech's broadest pipelines, but is challenged to find late-stage opportunities that are not fully reflected in valuation. Chico said as Elyea matures, it is challenging to justify a premium multiple and recommends moving to the sidelines given limited opportunities near-term to move shares higher.

  • 18

    May

  • 11

    Aug

  • 20

    Oct

REGN Regeneron
$319.61

-8.98 (-2.73%)

03/13/18
DBAB
03/13/18
NO CHANGE
Target $367
DBAB
Hold
Regeneron price target lowered to $367 from $397 at Deutsche Bank
Deutsche Bank analyst Navin Jacob lowered his price target for Regeneron Pharmaceuticals to $367 saying that while near term concerns on Dupixent are misplaced, he's concerned that Dupixent consensus estimates are too high over the mid and long term. The analyst keeps a Hold rating on Regeneron.
03/19/18
PIPR
03/19/18
NO CHANGE
Target $500
PIPR
Overweight
Piper remains buyer of Regeneron after Panorama trial results
Piper Jaffray analyst Christopher Raymond remains a buyer of Regeneron Pharmaceuticals following this morning's announcement that the Phase 3 Panorama clinical trial in Eylea met its 24-week primary endpoint in patients with nonproliferative diabetic retinopathy. While investors may continue to worry about Eylea's status among competitors like RTH258, DR represents a "new leg of growth and a key opportunity" for the Eylea franchise, Raymond tells investors in a research note. The analyst keeps an Overweight rating on Regeneron shares with a $500 price target.
03/22/18
PIPR
03/22/18
NO CHANGE
Target $182
PIPR
Overweight
Alnylam partnership deal with Regeneron a positive, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views Alnylam Pharmaceuticals (ALNY) partnership with Regeneron (REGN) to develop RNAi therapeutics to treat nonalcoholic steatohepatitis as a positive. Alnylam's expertise in RNAi delivery to hepatocytes complements therapeutic translation of Regeneron's discovery, Tenthoff tells investors in a research note. He remains confident in FDA approval of patisiran for ATTR amyloidosis by the August 11 action date and European approval in the second half of 2018. The analyst reiterates an Overweight rating on Alnylam with a $182 price target.
04/09/18
RAJA
04/09/18
DOWNGRADE
RAJA
Market Perform
Regeneron downgraded to Market Perform from Outperform at Raymond James

TODAY'S FREE FLY STORIES

05:50
04/25/18
04/25
05:50
04/25/18
05:50
General news
FX Action: USD-JPY corrected to a 108.98 low »

FX Action: USD-JPY…

CHKP

Check Point

$102.95

0.17 (0.17%)

05:38
04/25/18
04/25
05:38
04/25/18
05:38
Earnings
Check Point reports Q1 EPS $1.30, consensus $1.28 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

DISCA

Discovery

$23.94

0.17 (0.72%)

05:36
04/25/18
04/25
05:36
04/25/18
05:36
Hot Stocks
Discovery enters partnership with Digital Element »

Digital Element announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

SOGO

Sogou

$8.55

0.15 (1.79%)

05:35
04/25/18
04/25
05:35
04/25/18
05:35
Earnings
Breaking Earnings news story on Sogou »

Sogou sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SOGO

Sogou

$8.55

0.15 (1.79%)

05:34
04/25/18
04/25
05:34
04/25/18
05:34
Earnings
Sogou reports Q1 EPS 5c, consensus 3c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CYOU

Changyou.com

$28.79

-0.9 (-3.03%)

05:32
04/25/18
04/25
05:32
04/25/18
05:32
Earnings
Changyou.com sees Q2 EPS 38c-47c, consensus 53c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CYOU

Changyou.com

$28.79

-0.9 (-3.03%)

05:30
04/25/18
04/25
05:30
04/25/18
05:30
Earnings
Changyou.com reports Q1 adj. EPS (30c), may not compare to consensus 53c »

Reports Q1 revenue $137M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SOHU

Sohu.com

$30.26

-0.65 (-2.10%)

05:29
04/25/18
04/25
05:29
04/25/18
05:29
Earnings
Sohu.com sees Q2 EPS ($1.65)-($1.40), consensus ($1.32) »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SOHU

Sohu.com

$30.26

-0.65 (-2.10%)

05:28
04/25/18
04/25
05:28
04/25/18
05:28
Earnings
Breaking Earnings news story on Sohu.com »

Sohu.com reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SOHU

Sohu.com

$30.26

-0.65 (-2.10%)

05:26
04/25/18
04/25
05:26
04/25/18
05:26
Earnings
Sohu.com reports Q1 EPS ($2.39), consensus ($1.56) »

Reports Q1 revenue $455M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FOSL

Fossil

$14.21

-0.165 (-1.15%)

05:25
04/25/18
04/25
05:25
04/25/18
05:25
Hot Stocks
Fossil signs global license partnership with PUMA for watches, smartwatches »

Fossil Group and PUMA SE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$77.00

-0.595 (-0.77%)

05:23
04/25/18
04/25
05:23
04/25/18
05:23
Hot Stocks
Novartis announces launch of FocalView app »

Novartis announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 21

    May

  • 05

    Jun

EEFT

Euronet

$75.32

-1.04 (-1.36%)

05:22
04/25/18
04/25
05:22
04/25/18
05:22
Earnings
Breaking Earnings news story on Euronet »

Euronet sees Q2 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

EEFT

Euronet

$75.32

-1.04 (-1.36%)

05:21
04/25/18
04/25
05:21
04/25/18
05:21
Earnings
Euronet reports Q1 adj. EPS 73c, consensus 73c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ILMN

Illumina

$238.65

-7.19 (-2.92%)

05:02
04/25/18
04/25
05:02
04/25/18
05:02
Recommendations
Illumina analyst commentary  »

Illumina target upped to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 24

    May

  • 12

    Jun

PPG

PPG

$105.74

-3.12 (-2.87%)

04:56
04/25/18
04/25
04:56
04/25/18
04:56
Upgrade
PPG rating change  »

PPG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$151.02

-2.07 (-1.35%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Accenture to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AKAM

Akamai

$70.95

-0.73 (-1.02%)

, MRK

Merck

$60.08

-0.16 (-0.27%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Boardroom Resources to hold a summit »

2018 Boardroom Summit…

AKAM

Akamai

$70.95

-0.73 (-1.02%)

MRK

Merck

$60.08

-0.16 (-0.27%)

JNJ

Johnson & Johnson

$126.18

-0.65 (-0.51%)

LPLA

LPL Financial

$61.04

-0.5 (-0.81%)

GHC

Global Consumer Acquisition Corporation

$611.35

-4.65 (-0.75%)

FUN

Cedar Fair

$63.63

-0.44 (-0.69%)

DECK

Deckers Brands

$90.83

1.13 (1.26%)

CPB

Campbell Soup

$41.08

0.25 (0.61%)

BURBY

Burberry

AWK

American Water

$84.79

0.5 (0.59%)

BLK

BlackRock

$514.01

-5.79 (-1.11%)

STT

State Street

$101.07

-1.28 (-1.25%)

EA

Electronic Arts

$118.56

-0.99 (-0.83%)

HSY

Hershey

$92.81

-0.33 (-0.35%)

EQR

Equity Residential

$60.62

0.21 (0.35%)

APOG

Apogee Enterprises

$41.55

-1.11 (-2.60%)

VMC

Vulcan Materials

$111.32

-2.53 (-2.22%)

WEN

Wendy's

$16.84

-0.385 (-2.24%)

TWX

Time Warner

$96.02

-0.32 (-0.33%)

AMGN

Amgen

$171.91

-2.75 (-1.57%)

AGN

Allergan

$156.91

-2.98 (-1.86%)

CSCO

Cisco

$43.74

-0.49 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 15

    May

  • 17

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 30

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 12

    Jun

  • 14

    Jun

  • 23

    Oct

ANF

Abercrombie & Fitch

$27.03

0.265 (0.99%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Abercrombie & Fitch to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 12

    Jun

NVS

Novartis

$77.00

-0.595 (-0.77%)

, GSK

GlaxoSmithKline

$40.63

0.29 (0.72%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Drug Information Association to hold a forum »

Biostatistics Industry…

NVS

Novartis

$77.00

-0.595 (-0.77%)

GSK

GlaxoSmithKline

$40.63

0.29 (0.72%)

LLY

Eli Lilly

$80.09

-0.16 (-0.20%)

AZN

AstraZeneca

$35.13

-0.4 (-1.13%)

MRK

Merck

$60.08

-0.16 (-0.27%)

AMGN

Amgen

$171.91

-2.75 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 27

    Apr

  • 30

    Apr

  • 01

    May

  • 07

    May

  • 08

    May

  • 15

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 23

    Oct

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
UBS basic materials analyst to hold an analyst/industry conference call »

Basic Materials Analyst…

SBPH

Spring Bank Pharmaceuticals

$14.50

0.18 (1.26%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Spring Bank Pharmaceuticals management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 25

    May

IOVA

Iovance Biotherapeutics

$14.40

-0.1 (-0.69%)

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Iovance Biotherapeutics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

04:55
04/25/18
04/25
04:55
04/25/18
04:55
General news
Breaking General news story  »

Week of 4/20 MBA Mortgage…

CHPE

Chaparral Energy

04:55
04/25/18
04/25
04:55
04/25/18
04:55
Conference/Events
Chaparral Energy management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.